DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) has received an average rating of “Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $43.33.
A number of equities research analysts have issued reports on DICE shares. HC Wainwright started coverage on DICE Therapeutics in a research report on Monday, July 18th. They issued a “buy” rating and a $40.00 price target on the stock. Stifel Nicolaus assumed coverage on DICE Therapeutics in a report on Tuesday, September 6th. They issued a “buy” rating and a $37.00 price objective on the stock. Finally, Cantor Fitzgerald assumed coverage on DICE Therapeutics in a report on Wednesday, September 14th. They issued an “overweight” rating and a $36.00 price objective on the stock.
DICE Therapeutics Trading Up 2.8 %
DICE opened at $22.67 on Friday. The stock’s 50-day moving average price is $19.11 and its 200 day moving average price is $17.83. DICE Therapeutics has a 12-month low of $12.64 and a 12-month high of $38.18. The firm has a market cap of $866.22 million and a price-to-earnings ratio of -5.93.
DICE Therapeutics (NASDAQ:DICE – Get Rating) last posted its earnings results on Thursday, August 11th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.02). On average, research analysts forecast that DICE Therapeutics will post -2.33 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc increased its position in DICE Therapeutics by 265.1% during the second quarter. Legal & General Group Plc now owns 4,764 shares of the company’s stock worth $74,000 after buying an additional 3,459 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of DICE Therapeutics by 8.6% in the second quarter. Goldman Sachs Group Inc. now owns 14,150 shares of the company’s stock valued at $220,000 after purchasing an additional 1,115 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of DICE Therapeutics by 12.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 2,414,624 shares of the company’s stock valued at $37,475,000 after purchasing an additional 270,940 shares during the period. DAFNA Capital Management LLC increased its holdings in shares of DICE Therapeutics by 66.9% in the second quarter. DAFNA Capital Management LLC now owns 156,904 shares of the company’s stock valued at $2,435,000 after purchasing an additional 62,904 shares during the period. Finally, Driehaus Capital Management LLC increased its holdings in shares of DICE Therapeutics by 5.0% in the second quarter. Driehaus Capital Management LLC now owns 2,230,538 shares of the company’s stock valued at $34,618,000 after purchasing an additional 105,310 shares during the period. Institutional investors and hedge funds own 95.42% of the company’s stock.
About DICE Therapeutics
DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DICE Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and DICE Therapeutics wasn’t on the list.
While DICE Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: DICE Therapeutics, Inc. (NASDAQ:DICE) Given Consensus Recommendation of “Buy” by